COMMENTARY

• Challenges in a Post-AG Era: Ensuring a Reliable Supply System
  April 6, 2026

• Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
  April 1, 2026

• A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
  March 24, 2026

• Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
  March 11, 2026

• Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
  March 10, 2026

• ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use
  March 9, 2026

• G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
  February 25, 2026

• Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
  February 18, 2026

• Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
  February 9, 2026

• Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
  February 5, 2026

• TSE’s Growth Market Reform Puts Pressure on Biotechs
  January 27, 2026

• Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
  January 6, 2026

• Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
  December 22, 2025

• FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
  December 9, 2025

• MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
  November 17, 2025

• Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
  November 10, 2025

• The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
  October 27, 2025

• Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
  October 7, 2025

• Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
  October 6, 2025

• FPMAJ Chair’s Call for Blanket Drug Price Hike: Bold Pitch or Wild Throw?
  September 30, 2025

ページ